Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons

Archives of Medical Science, Journal Year: 2022, Volume and Issue: 18(5), P. 1133 - 1156

Published: Aug. 30, 2022

1. Visseren FLJ, Mach F, Smulders YM, . ESC National Cardiac Societies, Scientific Document Group. 2021 Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-37. Google Scholar

Language: Английский

---

Disorders of lipid metabolism. Clinical Guidelines 2023

Russian Journal of Cardiology, Journal Year: 2023, Volume and Issue: 28(5), P. 5471 - 5471

Published: June 3, 2023

The Russian Society of Cardiology (RKO) With the participation of: National for Study Atherosclerosis (NOA), Association Endocrinologists (RAE), Cardiosomatic Rehabilitation and Secondary Prevention (RosOKR), Scientific Medical Therapists (RNMOT), Eurasian Cardiologists, (EAT), Gerontologists Geriatricians

Language: Английский

---

The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis

European Journal of Preventive Cardiology, Journal Year: 2023, Volume and Issue: 30(18), P. 1975 - 1985

Published: Aug. 9, 2023

Abstract Aims There is good evidence showing that inactivity and walking minimal steps/day increase the risk of cardiovascular (CV) disease general ill-health. The optimal number steps their role in health is, however, still unclear. Therefore, this meta-analysis, we aimed to evaluate relationship between step count all-cause mortality CV mortality. Methods results We systematically searched relevant electronic databases from inception until 12 June 2022. main endpoints were An inverse-variance weighted random-effects model was used calculate Seventeen cohort studies with a total 226 889 participants (generally healthy or patients at risk) median follow-up 7.1 years included meta-analysis. A 1000-step increment associated 15% decreased [hazard ratio (HR) 0.85; 95% confidence interval (CI) 0.81–0.91; P < 0.001], while 500-step 7% decrease (HR 0.93; CI 0.91–0.95; 0.001). Compared reference quartile 3867 (2500–6675), Quartile 1 (Q1, steps: 5537), 2 (Q2, 7370), 3 (Q3, 11 529) lower for (48, 55, 67%, respectively; 0.05, all). Similarly, compared lowest as [median 2337, interquartile range 1596–4000), higher quartiles (Q1 = 3982, Q2 6661, Q3 10 413) linearly reduced (16, 49, 77%; Using restricted cubic splines model, observed nonlinear dose–response association (Pnonlineraly 0.001, both) progressively an increased count. Conclusion This meta-analysis demonstrates significant inverse daily more better over cut-off point only 2337

Language: Английский

---

Menopause and women’s cardiovascular health: is it really an obvious relationship?

Archives of Medical Science, Journal Year: 2022, Volume and Issue: 19(2), P. 458 - 466

Published: Dec. 10, 2022

Cardiovascular diseases are common for men and women but there differences between the sexes in terms of clinical symptoms, pathophysiology response to treatment. (CVD) is commonly underdiagnosed often tend have a lower perception risk. That can lead delayed diagnosis failed recognition symptoms. Women develop heart later than because protection reproductive phase their life. Once they enter menopause risk increases. Estrogen provides protective effect against disease women. Therefore, CVD increases after most cases. The presented work emphasizes importance menopausal period as time increasing It also monitoring health middle age, critical which early intervention strategies should be implemented reduce CVD.

Language: Английский

---

Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)

Progress in Cardiovascular Diseases, Journal Year: 2023, Volume and Issue: 79, P. 2 - 11

Published: March 7, 2023

Cardiovascular disease (CVD) is a chronic non-communicable (NCD) and the predominant cause of morbidity mortality worldwide. Substantial reductions in CVD prevalence have been achieved recent years by attenuation risk factors (particularly hypertension dyslipidaemias) primary secondary prevention. Despite remarkable success lipid lowering treatments, statins particular, reducing CVD, there still an unmet clinical need for attainment guideline lipid-targets even 2/3 patients. Bempedoic acid, first in-class inhibitor ATP-citrate lyase presents new approach to lipid-lowering therapy. By endogenous production cholesterol, upstream rate-limiting enzyme HMG-CoA-reductase, i.e., target statins, bempedoic acid reduces circulating plasma concentrations low-density lipoprotein cholesterol (LDL-C), major adverse events (MACE). has potential contribute reduction not only as monotherapy, but further part combination therapy with ezetimibe, LDL-C up 40%. This position paper International Lipid Expert Panel (ILEP) summarises evidence around efficacy safety practical recommendations its use, which complement 'lower-is-better-for-longer' management, applied across international guidelines management risk. Practical evidence-based guidance provided relating use atherosclerotic familial hypercholesterolaemia, statin intolerance. Although are no sufficient data avilable role prevention favourable effects on glucose inflammatory markers makes this drug rational choice patient-centred care specific groups

Language: Английский

---

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Pharmacological Research, Journal Year: 2023, Volume and Issue: 189, P. 106679 - 106679

Published: Feb. 8, 2023

Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition affecting around 10–25% of the general adult population, 15% children, and even > 50% individuals who have type 2 diabetes mellitus. It major cause liver-related morbidity, cardiovascular (CV) mortality death. In addition to being initial step irreversible alterations liver parenchyma causing cirrhosis, about 1/6 those develop NASH are at risk also developing CV disease (CVD). More recently acronym MAFLD (Metabolic Associated Disease) has been preferred by many European US specialists, providing clearer message on metabolic etiology disease. The suggestions for management NAFLD like recommended guidelines CVD prevention. this context, approach prescribe physical activity dietary changes effect weight loss. Lifestyle change in patient supplemented some use nutraceuticals, but evidence based these remains uncertain. aim Position Paper was summarize clinical relating nutraceuticals NAFLD-related parameters. Our reading data that whilst studied relation NAFLD, none sufficient recommend their routine use; robust trials required appropriately address efficacy safety.

Language: Английский

---

Lipoprotein(a) and cardiovascular disease

The Lancet, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Language: Английский

---

Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels

Archives of Medical Science, Journal Year: 2024, Volume and Issue: 20(1), P. 8 - 27

Published: Jan. 30, 2024

Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and specific apolipoprotein(a). The blood concentration Lp(a) approximately 90% genetically determined, the main genetic factor determining levels size apo(a) isoform, which determined by number KIV2 domain repeats. isoform inversely proportional to Lp(a). strong independent cardiovascular risk factor. Elevated ≥ 50 mg/dl (≥ 125 nmol/l) are estimated occur in more than 1.5 billion people worldwide. However, determination performed far too rarely, including Poland, where, fact, it only since 2021 guidelines Polish Lipid Association (PoLA) five other scientific societies that measurements have begun be performed. Determination concentrations not easy due to, among things, different sizes isoforms; however, currently available certified tests make possible distinguish between with low high degree precision. In 2022, first for management patients elevated lipoprotein(a) were published European Atherosclerosis Society (EAS) American Heart (AHA). result work experts from two their aim provide clear, practical recommendations levels.

Language: Английский

---

Effect of diet low in omega-6 polyunsaturated fatty acids on the global burden of cardiovascular diseases and future trends: evidence from the Global Burden of Disease 2021

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 11

Published: Jan. 7, 2025

This research analyzes the worldwide impact of cardiovascular diseases (CVD) associated with low consumption omega-6 polyunsaturated fatty acids, utilizing data from 2021 Global Burden Disease Study. The study explored influence diets deficient in acids on CVD across global, regional, and national levels. It examined variations different age groups genders analyzed relationship between disease burden socio-demographic index (SDI). Furthermore, it employed an ARIMA model to project future prevalence linked insufficient intake until 2050. In 2021, was roughly 737.88 thousand deaths 17.87 million disability-adjusted life years (DALYs) due CVD, showing a decreasing trend this health throughout period. most significant effects were seen individuals aged 75 older, higher noted males. Forecasts suggest likely declines regions high SDI. On level, like Russia various countries North Africa Middle East might experience increasing challenges related by 2030 These results highlight critical need for preventive strategies stress importance managing dietary patterns mitigate risks.

Language: Английский

---

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)

Published: Nov. 28, 2022

Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, only about 1/4 being on low-density lipoprotein cholesterol (LDL-C) target. There are many reasons this, including physicians' inertia, diabetologists and cardiologists, therapy nonadherence, but also underusage underdosing lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In last several years there a big debate stratification DMT2 patients, strong indications that all should be at least high disease (CVD) risk. Moreover, we have finally drugs, not allow for effective reduction LDL-C do increase new onset (NOD), and/or glucose impairment; opposite, some them might effectively improve control. One most interesting pitavastatin, which now available Europe, best metabolic profile within statins (no NOD, improvement fasting blood glucose, HOMA-IR, HbA1c), bempedoic acid (with potential NOD risk), innovative therapies-PCSK9 inhibitors inclisiran no increase, forthcoming therapies, apabetalone obicetrapib-for latter possibility even decreasing number diagnosed prediabetes DMT2. Altogether, nowadays individualize goal without any control worsening, consequence reduce CVD complications progression atherosclerosis this patients' group.

Language: Английский

---